[ad_1]
Image source: Pfizer
(Reuters) – Pfizer Inc and its partner BioNTech are planning to give volunteers who received a placebo in their COVID-19 vaccine trial an option to receive a first dose of the vaccine before March 1, 2021, while staying within the study.
The trial vaccine transition option allows all participants 16 years of age and older the option of finding out if they received the placebo, “and participants who learn they received the placebo have the option of receiving the investigational vaccine while they stay in the studio. ” the companies said on their website here for the trial participants.
Sign up to receive our Daily Fix delivered to your inbox 5 days a week
The US Food and Drug Administration and a panel of its external advisers have raised concerns about Pfizer’s “unmasking” plan, saying it could make it difficult to collect the safety and efficacy data required to gain approval. total of the vaccine by the FDA.
Trial participants who received the placebo will have two doses of the investigational vaccine reserved for them within the study, the companies said on the website.
“The study physician will follow the latest guidelines from the US Centers for Disease Control and Prevention and their local health authorities to offer the vaccine transition option to participants on a prioritized basis,” said the Business.
Report of Aakriti Bhalla in Bengaluru; Editing by Daniel Wallis
_____
Source: Reuters
Next page
[ad_2]
